Clinical Trial Update: RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Rituximab versus Ocrelizumab for relapsing-remitting multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)
• Rituximab (rituximab)

Snippet

Sponsor: Rennes University Hospital | Conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: RECRUITING